ReviewDrug safety2016
Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence.
Review in Drug safety, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology.Journal of psychopharmacology (Oxford, England) · 2026Guideline
- Baclofen for alcohol use disorder.The Cochrane database of systematic reviews · 2023Pooled it
- Pooled it
- Serious adverse events reported in placebo randomised controlled trials of oral naltrexone: a systematic review and meta-analysis.BMC medicine · 2019Pooled it
- Reduction in Drinking was Associated With Improved Clinical Outcomes in Women With HIV Infection and Unhealthy Alcohol Use: Results From a Randomized Clinical Trial of Oral Naltrexone Versus Placebo.Alcoholism, clinical and experimental research · 2019Trial
- Article
- Alcohol Abstinence, Adherence, and Attitudes toward Disulfiram Treatment for Alcohol Dependence among Patients Attending a Tertiary Care Setting in North India.Addiction & health · 2024Article
- Safety assessment of disulfiram: real-world adverse event analysis based on FAERS database.Frontiers in psychiatry · 2024Article
- The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.Frontiers in cellular and infection microbiology · 2022Article
- Real-world effectiveness of pharmacological treatments of alcohol use disorders in a Swedish nation-wide cohort of 125 556 patients.Addiction (Abingdon, England) · 2021Article
- [Pharmacotherapy of alcohol withdrawal: update and new developments].Der Nervenarzt · 2021Review
- Evaluation and Management of Alcohol use Disorder among Older Adults.Current geriatrics reports · 2021Review
- Understanding the client characteristics of Aboriginal residential alcohol and other drug rehabilitation services in New South Wales, Australia.Addiction science & clinical practice · 2020Article
- Disulfiram-Induced Acute Liver Injury.Case reports in hepatology · 2020Article
- Deterrent Action of Acamprosate: A Case Report.Addiction & health · 2019Article
- Access to care for people with alcohol use disorder in France: a mixed-method cross-sectional study protocol (ASIA).BMJ open · 2018Article
- [Diagnosis, differential diagnosis and therapy of substance use disorders in general hospital (general section)].Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2018Review
- The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.Frontiers in psychiatry · 2018Review
- Baclofen in the Treatment of Patients With Alcohol Use Disorder and Other Mental Health Disorders.Frontiers in psychiatry · 2018Review
- Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.Alcoholism, clinical and experimental research · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
4 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alcohol use disorders (AUD) cause significant morbidity and mortality worldwide, but pharmacological treatments for them are underused, despite evidence of efficacy. Acamprosate, naltrexone, nalmefene and disulfiram are all approved in one or more region for the treatment of AUD. Baclofen currently has a temporary indication in France. Safety considerations for using psychopharmacological treatments in this patient group include the impact of concurrent alcohol consumption at high levels; multiple physical comorbidities that may interfere with pharmacological effects, distribution and metabolism; and concomitant medication for the treatment of comorbid physical and psychiatric conditions. The five drugs, including an extended-release injectable suspension of naltrexone, have different safety profiles that need to be balanced with the treatment objective (initiation or continuation of abstinence, or reduction of drinking), individual patient preferences and comorbid conditions. Appropriate treatment will be based on the unique risk-benefit profile in each case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.